Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyu-Pyo Kim

Showing results (101-110 of 217) with videos related to

Pageof 22
Sort By:
European Journal of Dermatology : EJD|December 15, 2012
Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancerJae-Cheol Jo, Yong Sang Hong, Kyu-pyo Kim, et al.
The Korean Journal of Gastroenterology = Taehan Sohwagi Hakhoe Chi|February 24, 2004
[Clinical characteristics of 17 cases of autoimmune chronic pancreatitis]Kyu-Pyo Kim, Myung- Hwan Kim, Yun Jung Lee, et al.
The Lancet. Oncology|October 17, 2021
Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b studyChanghoon Yoo, Kyu-Pyo Kim, Jae Ho Jeong, et al.
Clinical Colorectal Cancer|August 6, 2018
Prognostic Value of the Microsatellite Instability Status in Patients With Stage II/III Rectal Cancer Following Upfront SurgeryChung Ryul Oh, Jeong Eun Kim, Jihoon Kang, et al.
Cancer Research and Treatment|December 23, 2017
Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer OnlySu-Jin Shin, Hosub Park, You-Na Sung, et al.
Cancer Chemotherapy and Pharmacology|May 22, 2013
Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasisJun Ho Ji, Se Hoon Park, Jeeyun Lee, et al.
Anticancer Research|May 18, 2012
The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2Dok Hyun Yoon, Jae-Sik Shin, Dong-Hoon Jin, et al.
Annals of Surgical Oncology|November 1, 2024
Survival Outcomes According to NCCN Criteria for Resection Following Neoadjuvant Therapy for Patients with Localized Pancreatic CancerJong Keon Jang, Jae Ho Byun, Se Jin Choi, et al.
Abdominal Radiology (New York)|May 27, 2024
Comparison of the different versions of NCCN guidelines for predicting margin-negative resection of pancreatic cancer in patients undergoing upfront surgeryEun Joo Park, Jong Keon Jang, Jae Ho Byun, et al.
Journal of Hepato-Biliary-Pancreatic Sciences|June 3, 2022
Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resection vs CT-determined resectabilityJong Keon Jang, Se Jin Choi, Jae Ho Byun, et al.
Pageof 22

Showing results (101-110 of 217) with videos related to

Sort By:
Pageof 22
European Journal of Dermatology : EJD|December 15, 2012
Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancerJae-Cheol Jo, Yong Sang Hong, Kyu-pyo Kim, et al.
The Korean Journal of Gastroenterology = Taehan Sohwagi Hakhoe Chi|February 24, 2004
[Clinical characteristics of 17 cases of autoimmune chronic pancreatitis]Kyu-Pyo Kim, Myung- Hwan Kim, Yun Jung Lee, et al.
The Lancet. Oncology|October 17, 2021
Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b studyChanghoon Yoo, Kyu-Pyo Kim, Jae Ho Jeong, et al.
Clinical Colorectal Cancer|August 6, 2018
Prognostic Value of the Microsatellite Instability Status in Patients With Stage II/III Rectal Cancer Following Upfront SurgeryChung Ryul Oh, Jeong Eun Kim, Jihoon Kang, et al.
Cancer Research and Treatment|December 23, 2017
Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer OnlySu-Jin Shin, Hosub Park, You-Na Sung, et al.
Cancer Chemotherapy and Pharmacology|May 22, 2013
Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasisJun Ho Ji, Se Hoon Park, Jeeyun Lee, et al.
Anticancer Research|May 18, 2012
The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2Dok Hyun Yoon, Jae-Sik Shin, Dong-Hoon Jin, et al.
Annals of Surgical Oncology|November 1, 2024
Survival Outcomes According to NCCN Criteria for Resection Following Neoadjuvant Therapy for Patients with Localized Pancreatic CancerJong Keon Jang, Jae Ho Byun, Se Jin Choi, et al.
Abdominal Radiology (New York)|May 27, 2024
Comparison of the different versions of NCCN guidelines for predicting margin-negative resection of pancreatic cancer in patients undergoing upfront surgeryEun Joo Park, Jong Keon Jang, Jae Ho Byun, et al.
Journal of Hepato-Biliary-Pancreatic Sciences|June 3, 2022
Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resection vs CT-determined resectabilityJong Keon Jang, Se Jin Choi, Jae Ho Byun, et al.
Pageof 22